Published in Health Business Week, November 18th, 2005
The "Biotechnology Future Investment Expansion (BIOFIX) Act of 2005" would amend Section 382 of the Internal Revenue Code. It will foster biotechnology companies' access to capital by expanding use of net operating losses (NOLs) after becoming profitable or following a business-driven merger with another biotech company.
"This legislation updates our tax laws to recognize the uniquely capital-intensive nature of the biotechnology industry. BIO...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week